Comparative analysis of modern approaches to the correction of hyperprolactinemia in adolescent girls with menstrual dysfunction




hyperprolactinemia, menstrual irregularities, hormonal profile of adolescent girls, prolactin, Cyclodynon


Purpose of the study: a comparative analysis of the hormonal profile in patients with menstrual disorders on the background of hyperprolactinemia during puberty after different treatments.

Materials and methods. 94 adolescent girls with formation of menstrual function were examined. The mean age of patients was 14.0 ± 1.5 years. Participants were divided into groups according to the management: I (main) group – girls with menstrual disorders on the background of hyperprolactinemia during puberty, who received differentiated approach proposed by study authors (n = 33); II (comparison) group – girls with menstrual disorders on the background of hyperprolactinemia during puberty, who received conventional treatment (n = 31); III (control) group – healthy girls in puberty (n = 30).

A high-calorie, balanced, protein-enhanced diet and psychotherapy for girls with severe weight loss; a high-calorie, balanced, protein-enhanced diet for girls with insufficient body weight; physical training for girls with normal weight and overweight was recommended. A comprehensive anti-stress therapy for high levels of personal and situational anxiety was recommended. The drug with a mild dopaminergic effect Cyclodynon® to correct prolactin levels and normalize menstrual function in adolescent girls was used.

Results. The obtained data indicate a decrease in ovarian reserve in girls with menstrual disorders on the background of hyperprolactinemia from adolescence age. Dynamics of prolactin reduction in girls with hyper- and hypomenstrual syndromes and amenorrhea in group I was faster compared to group II as a result of treatment. Prolactin level in patients with hypermenstrual syndrome as early as 3 months after the start of therapy did not differ from its level in healthy girls; in patients with hypomenstrual syndrome and amenorrhea – after 6 months. Therapeutic effect persisted throughout the first year of observation.

Conclusions. A differentiated approach to the management of patients with menstrual disorders on the background of hyperprolactinemia during puberty was found to be twice as effective as in conventional measures.

Author Biographies

O. V. Gorbunova, P.L. Shupyk NMAPE of the MoH of Ukraine, Kyiv

MD, associate professor, head of the Department of Obstetrics, Gynaecology and Perinatology

I. O. Yurchenko, P.L. Shupyk NMAPE of the MoH of Ukraine, Kyiv

Graduate student, Department of Obstetrics, Gynaecology and Perinatology


Vovk, I.B., Vdovichenko, Y.P., Yuzko, O.M., et al.; eds. Gynecology of a child and an adult. Kyiv (2011): 424 p.

Vovk, I.B., Kornatska, A.G., Peterburzhska, V.F. “Normalization of menstrual disorders of adolescent girls – a guarantee of reproductive health of women.” Health of Ukraine 2 (2019): 27–35.

World Health Organization. International Statistical Classification of Diseases and Related Health Problems of the Tenth Review (ICD-10). Geneva. WHO (2016). Available from: [].

Gerasymova, T.V. “Abnormal uterine bleeding during puberty (lecture thesis).” Obstetrics. Gynecology. Genetics 2.2 (2016): 81–90.

Hryshchenko, O.V., Bobrytskaia, V.V. “New patterns of treatment of menstrual disorders – unification of the method.” Reproductive endocrinology 3.47 (2019): 26–32.

Yefimenko, O.А. “Hyperprolactinemia in gynecological practice.” Medical aspects of women's health. Special issue (2018): 27–9.

Kyryliuk, M.L. “Hyperprolactinemic syndrome: etiology, pathogenesis, clinic, diagnosis, modern treatment.” Clinical endocrinology and endocrine surgery 4 (2013): 52–61.

Mazur, L.P., Marushchak, M.I., Naumova, L.V., et al. “Clinical case of hyperprolactinemia combined with increased thyroid stimulating hormone.” Bulletin of the medical and biological research 2 (2019): 87–9.

Manashchuk, S.I., Mykhailyuta, M.A., Hananova, F.K. “Abnormal uterine bleeding in adolescent girls with hyperprolactinemia syndrome: diagnosis and treatment.” Obstetrics. Gynecology. Genetics 5.1 (2019): 49–57.

Mykhailyuta, M.A. “Features of diagnosis and treatment of menstrual disorders in hyperprolactinemia in puberty and reproductive age.” Obstetrics. Gynecology. Genetics 3.4 (2017): 29–34.

Nikiforov, O.A., Lomeyko, O.O., Avramenko, N.V. “Experience of management of patients with hyperprolactinemia in preparation for auxiliary reproductive technologies.” Bulletin of biology and medicine problems 4.3 (2017): 177–80.

Prystupiuk, O. “Syndrome of hyperprolactinemia.” International Journal of Endocrinology 6 (2012): 63–6.

Redkin, R., Orlovetskaya, N., Dankevych, O. “Hyperprolactinemia as a side effect of drugs.” Pharmacist Practitioner 11 (2018): 36–7.

Tatarchuk, T.F., Kosei, N.V., Regeda, S.I., et al. “Hyperprolactinemia in the genesis of stress-induced infertility. Possibilities of phytotherapy.” Women's Health 3 (2017): 28–36.

Tronko, M.D., Antypkin, Y.G., Kaminskyi, V.V., et al. “National consensus on Management of Patients with Hyperprolactinemia.” Reproductive Endocrinology 4.30 (2016): 8–18.

Tsysar, Y.V. “Peculiarities of the course of puberty age of girls with menstrual dysfunction.” Bukovynian Medical Bulletin 22.2 (2018): 109–12.

Berga, S., Genazzani, A.R., Naftolin, F., Petraglia, F. “Menstrual Cycle Related Disorders.” Frontiers in Gynecological Endocrinology 7.1 (2019): 225.

Haddad, R.A., Giacherio, D., Barkan, A.L. “Interpretation of common endocrine laboratory tests: technical pitfalls, their mechanisms and practical considerations.” Clin Diabetes Endocrinol 5 (2019): 12. DOI: 10.1186/s40842-019-0086-7

Kalsi, A.K., Halder, A., Jain, M., et al. “Prevalence and reproductive manifestations of macroprolactinemia.” Endocrine 63 (2019): 332–40. DOI: 10.1007/s12020-018-1770-6

Krysiak, R., Marek, B., Okopień, B. “Cardiometabolic risk factors in young women with macroprolactinaemia.” Endokrynol Pol 70 (2019): 336–41. DOI: 10.5603/EP.a2019.0013

Levine, S., Muneyyirci-Delale, O. “Stress-Induced Hyperprolactinemia: Pathophysiology and Clinical Approach.” Obstet Gynecol Int 2018 (2018): 9253083. DOI: 10.1155/2018/9253083

Matalliotakis, M., Koliarakis, I., Matalliotaki, C., et al. “Clinical manifestations, evaluation and management of hyperprolactinemia in adolescent and young girls: a brief review.” Acta Biomed 90 (2019): 149–57. DOI: 10.23750/abm. v90i1.8142

Melmed, S., Casanueva, F.F., Hoffman, A.R., et al.; Endocrine Society. “Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab 96.2 (2011): 273–88.

Tritos, N.A., Klibanski, A. “Prolactin and Its Role in Human Reproduction.” Yen Jaffe’s Reprod Endocrinol (2019): 58–74.e8. DOI: 10.1016/B978-0-323-47912-7.00003-2

Vilar, L., Abucham, J., Albuquerque, J.L., et al. “Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.” Arch Endocrinol Metab 62.2 (2018): 236–63.